Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02475629 · ClinicalTrials.gov registry record · Phase 3
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV
A Phase 3 study, sponsored by TaiMed Biologics.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT02475629 is a Phase 3 study that has completed, run by TaiMed Biologics. The registered enrollment target is 40 participants.
The verdict
NCT02475629, a Phase 3 study, has completed, sponsored by TaiMed Biologics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1.
Interventions
- DRUG Optimized Background Regimen (OBR)
- BIOLOGICAL ibalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02475629
The ClinicalTrials.gov registry entry for NCT02475629 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TaiMed Biologics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Optimized Background Regimen (OBR) is the first listed.
NCT02475629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02475629 about?
NCT02475629 is a clinical study titled "Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV". This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1.
What is the current status of trial NCT02475629?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2015-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02475629?
The interventions under investigation include: Optimized Background Regimen (OBR) (DRUG), ibalizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02475629?
This trial is sponsored by TaiMed Biologics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.